Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: An analysis of p16/MTS1 tumor suppressor gene inactivation

Cancer Research

Volumn 58, Issue 2, 1998, Pages 237-240

  Muscarella, Peter ^a   Melvin, W Scott ^a   Fisher, William E ^a   Foor, John ^a   Ellison, E Christopher ^a   Herman, James G ^b   Schirmer, William J ^a   Hitchcock, Charles L ^a   DeYoung, Barry R ^a   Weghorst, Christopher M ^a,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GASTRINOMA; GENE DELETION; GENE REPRESSION; HUMAN; HUMAN TISSUE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; GASTRINOMA; GENE DELETION; GENES, P16; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 0031984215     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Zollinger, R. M., and Ellison, E. H. Primary peptic ulceration of the jejunum associated with islet cell tumors of the pancreas. Ann. Surg., 142: 709-728, 1955.
2. Passaro, E., Stabile, B. E., and Howard, T. J. Contributions of the Zollinger-Ellison syndrome. Am. J. Surg., 161: 203-206, 1991.
3. Evers, B. M., Rady, P. L., Sandoval, K., Arany, I., Tyring, S. K., Sanchez, R. L., Nealon, W. H., Townsend, C. M., and Thompson, J. C. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann. Surg., 219: 596-605, 1994.
4. Eubanks, P. J., Sawicki, M. P., Samara, G. J., Gatti, R., Nakamura, Y., Tsao, D., Johnson, C., Hurwitz, M., Wan, Y. Y., and Passaro, E. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am. J. Surg., 167: 180-185, 1994.
5. Bale, A. E., Norton, J. A., Wong, E. L., Fryburg, J. S., Maton, P. N., Oldfield, E. H., Streeten, E., Aurbach, G. D., Brandi, M. L., Friedman, E., Spiegel, A. M., Taggart, R. T., and Marx, S. J. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res., 51: 1154-1157, 1991.
6. Sawicki, M. P., Wan, Y. Y., Johnson, C. L., Berenson, J., Gatti, R., and Passaro, E. Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. Hum. Genet., 89: 445-449, 1992.
7. Chandrasekharappa, S. C., Guru, S. C., Manickam, P., Olufemi, S., Collins, F. S., Emmert-Buck, M. R., Debelenko, L. V., Zhuang, Z., Lubensky, I. A., Liotta, L. A., Crabtree, J. S., Wang, Y., Roe, B. A., Weisemann, J., Boguski, M. S., Agarwal, S. K., Kester, M. B., Kim, Y. S., Heppner, C., Dong, Q., Spiegel, A. M., Burns, A. L., and Marx, S. J. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (Washington DC), 276: 404-407, 1997.
8. Yoshimoto, K., Iwahana, H., Fukuda, A., Sano, T., Katsuragi, M., Saito, S., and Itakura, M. ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res., 83: 1057-1062, 1992.
9. Yashiro, T., Fulton, N., Hara, H., Yasuda, K., Montag, A., Yashiro, N., Straus, F., Ito, K., Aiyoshi, Y., and Kaplan, E. L. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery, 114: 758-764, 1993.
10. Caldas, C., Hahn, S. A., daCosta, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16(MTS-1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
11. Liu, Q., Yan, Y-Z., McClure, M., Nakagawa, H., Fujumura, F., and Rustgi, A. K. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic cancer cell lines. Oncogene, 10: 619-622, 1995.
12. Naumann, M., Savitskaia, N., Elert, C., Schramm, A., Kalthoff, H., and Schmiegel, W. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology, 110: 1215-1224, 1996.
13. Huang, L., Goodrwo, T. L., Zhang, S-Y., Klein-Szanto, A. J. P., Chang, H., and Ruggeri, B. A. Deletion and mutation analysis of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res., 56: 1137-11411 1996.
14. Chen, W., Weghorst, C. M., Sabourin, C. L. K., Wang, Y., Wang, D., Bostwick, D. G., and Stoner, G. D. Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis (Lond.), 17: 2603-2607, 1996.
15. Hongyo, T., Buzard, G. S., Calvert, R. J., and Weghorst, C. M. "Cold SSCP": a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res., 121: 3637-3642, 1993.
16. Herman, J. G., Graf, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93: 9821-9826, 1996.
17. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
18. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J-P. J., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
19. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Bean, R. W., VanTornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
20. Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., and Herman, J. G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res., 57: 3126-3130, 1997.
21. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16(CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.
22. Makos, M. W., Biel, M. A., El Deiry, W., Nelkin, B. D., Issa, J-P., Cavanee, W. K., Kuerbitz, S. J., and Baylin, S. B. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med., 1: 570-577, 1995.
23. Swafford, D. S., Middleton, S. K., Palmisano, W. A., Nikula, K. J., Tesfaigzi, J., Baylin, S. B., Herman, J. G., and Belinsky, S. A. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol. Cell. Biol., 17: 1366-1374, 1997.